Conference Coverage

Contralateral nodal thyroid metastases show slow progression

View on the News

Recent experience discounts reflexive metastasis resection

The finding reported by Dr. Hartl is consistent with recent experience with other tumor types, like prostate cancer, that often show low aggressiveness. The need to routinely resect what may be indolent microscopic metastases remains a big open question.

The dilemma for thyroid cancer was nicely summarized by Gilbert Welch, MD, and his associates who highlighted the risk of overdiagnosing thyroid cancer with aggressive screening. In South Korea, this resulted in a 15-fold increase in thyroid cancer diagnoses between 1993 and 2011, which led to substantial increases in the rates of thyroidectomy including patients with tumors too small to warrant surgery (N Engl J Med. 2014 Nov 6;371[19]:1765-7).

Dr. Pamela Hartzband endocrinologist at Beth Israel Deaconess Medical Center in Boston Mitchel L. Zoler/Frontline Medical News

Dr. Pamela Hartzband

Some thyroid oncologists now just monitor small metastases in selected thyroid cancer patients and defer surgery. Patients who are good candidates for deferred surgery and surveillance include elderly patients and those with comorbidities, for whom surgery is not a good option, as well as patients with a condition that seems likely to soon lead to death before the thyroid cancer becomes clinically significant.

Pamela Hartzband, MD , is an endocrinologist at Beth Israel Deaconess Medical Center in Boston. She had no disclosures. She made these comments in an interview.


 

AT WCTC 2017

– More than a third of 63 patients with unilateral papillary thyroid carcinoma and ipsilateral lymph node metastases also had occult, contralateral, lateral-neck lymph nodes with metastases, but the low reported rate of contralateral neck recurrence has raised the question of whether routine resection of these contralateral lymph nodes benefits patients.

“Prophylactic contralateral lateral-neck dissection may not be relevant for patients with unilateral N1b tumors,” Dana Hartl, MD, PhD, said at the World Congress on Thyroid Cancer.

Dr. Dana Hartl chief of thyroid surgery at Gustave Roussy in Paris. Mitchel L. Zoler/Frontline Medical News

Dr. Dana Hartl

Routine, prophylactic surgical resection of contralateral, lateral-neck lymph nodes in these patients “was our protocol for the past 20 years. I think we will change our practice” based on these findings, predicted Dr. Hartl, chief of thyroid surgery at Gustave Roussy in Paris.

She envisioned a more targeted approach to using surgical resection of contralateral, lateral-neck lymph nodes. “We would still do this surgery for patients with lots of big, bulky nodules; it just takes an additional 10-20 minutes. It’s not that long or morbid. For patients with lots of [affected] nodes, you’ve got to clear it out. But for a patient with a small, level III node on one side I will no longer do [prophylactic, contralateral, lateral-neck lymph node removal].”

Dr. Hartl and her associates reviewed records for 63 patients with unilateral, unifocal papillary thyroid carcinoma who underwent prophylactic, contralateral, lymph node removal during 1997-2016. They ranged from 11-84 years old, and 60% had extrathyroidal extension of their primary tumor. The patients averaged having four lymph nodes with metastatic cells in the ipsilateral lateral neck, an average of five affected lymph nodes in the ipsilateral central neck, and an average of two affected lymph nodes in the contralateral central neck.

Among the 63 patients, 23 (37%) had metastases-containing lymph nodes at levels III and IV in the contralateral lateral neck, with a range of 1-17 metastases per node. All nodes were less than 1 cm in diameter. Extracapsular spread had occurred in 11 of the 23 cases.

The relatively frequent presence of metastases in the contralateral, lateral-neck lymph nodes contrasted with the reported low 5%-15% rate of recurrence in these lymph nodes in patients with N1b disease, Dr. Hartl said.

The analysis identified two factors that significantly linked with having contralateral, lateral-neck metastases: having a bilateral tumor with contralateral microcancer, or having at least four lymph nodes positive for metastases in the ipsilateral central compartment, she reported. When patients had fewer than five positive lymph nodes in the ipsilateral central neck, their risk for occult metastases in contralateral lymph nodes was 26%.

“It’s not very strong data; we were a little disappointed” with the results, Dr. Hartl said.

On Twitter @mitchelzoler

Recommended Reading

Cabozantinib shows promise for carcinoid tumors, pNET
MDedge Hematology and Oncology
Standardize opioid prescribing after endocrine neck surgery, researchers say
MDedge Hematology and Oncology
Peptide vaccine shows early promise in ovarian, endometrial cancers
MDedge Hematology and Oncology
Thyroid cancer incidence: It’s not all good news
MDedge Hematology and Oncology
Temozolomide may help half of patients with aggressive pituitary tumors
MDedge Hematology and Oncology
Metformin linked with better survival in RCC patients with diabetes
MDedge Hematology and Oncology
USPSTF: No thyroid cancer screening for asymptomatic adults
MDedge Hematology and Oncology
VIDEO: Less follow-up proposed for low-risk thyroid cancer
MDedge Hematology and Oncology
VIDEO: Lenvatinib’s real-world thyroid cancer performance matches trial
MDedge Hematology and Oncology
Revised thyroid Bethesda System resets malignant risks
MDedge Hematology and Oncology

Related Articles